Skip to content

US · CNTX · BIOTECHNOLOGY

Context Therapeutics Inc. (CNTX) intrinsic value and stock valuation

$0.16as of 2026-11-21 · Mkt cap 63.67M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Context Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values CNTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CNTX’s statements →

Context Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Philadelphia, PA 19103 contexttherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-36.12M
20192025
Free cash flow
-$-26.42M
20192025
Total equity
$60.5M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-39.7M-$-29.92M-$-25.07M-$-15.38M-$-10.53M
Net income-$-36.12M-$-26.73M-$-23.96M-$-14.84M-$-10.46M
EPSd-$-379.45K-$-457.55K-$-1.5M-$-929.24K-$-3.7M
Operating cash flow-$-26.39M-$-14.56M-$-21.05M-$-13.55M-$-8.8M
Capital expenditure-$-30K-$-14.76M$0.00-$-540K-$-250K
Free cash flow-$-26.42M-$-29.31M-$-21.05M-$-14.09M-$-9.05M
Total assets$68.5M$98.1M$16.1M$38M$51.3M
Total debt$110K$220K$0.00$60K$0.00
Net debt-$-65.88M-$-94.21M-$-14.45M-$-35.44M-$-49.64M
Total equity$60.5M$95.3M$11.9M$34.8M$48.3M
Cash and short-term investments$66M$94.4M$14.5M$35.5M$49.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$31.9M$22.7M$17.8M$7.09M$3.81M
Selling, general and administrative expenses$7.85M$7.22M$7.29M$7.79M$3.63M
Other expenses$0.00$0.00$0.00$500K$3.09M
Operating expenses$39.7M$29.9M$25.1M$15.4M$10.5M
Cost and expenses$39.7M$29.9M$25.1M$15.4M$10.5M
Interest income$3.38M$3.2M$1.16M$550K$0.00
Interest expense$0.00$0.00$0.00$550K$60K
Depreciation and amortization$20K$10K$10K$10K-$-3.09M
Ebitda-$-36.11M-$-26.71M-$-23.95M-$-14.87M-$-10.53M
Operating income-$-39.7M-$-29.92M-$-25.07M-$-15.38M-$-10.53M
Total other income/expenses, net$3.58M$3.2M$1.11M$550K$70K
Income before tax-$-36.12M-$-26.73M-$-23.96M-$-14.84M-$-10.46M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-36.12M-$-26.73M-$-23.96M-$-14.84M-$-10.46M
Weighted average shares outstanding$95.2M$58.4M$16M$16M$2.83M
Weighted average diluted shares outstanding$95.2M$58.4M$16M$16M$2.83M
Balance sheet
20252024202320222021
Cash and short-term investments$66M$94.4M$14.5M$35.5M$49.6M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$68.4M$97.9M$16.1M$37.9M$51.3M
Property, plant and equipment, net$140K$230K$20K$80K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$50K
Total non-current assets$140K$230K$20K$110K$50K
Total assets$68.5M$98.1M$16.1M$38M$51.3M
Accounts payable$2.53M$1.45M$2.38M$940K$1.83M
Short-term debt$110K$110K$0.00$60K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.02M$2.75M$4.19M$3.21M$3.03M
Long-term debt$0.00$110K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$110K$0.00$0.00$0.00
Capital lease obligations$110K$220K$0.00$60K$0.00
Total liabilities$8.02M$2.86M$4.19M$3.21M$3.03M
Common stock$90K$90K$20K$20K$20K
Retained earnings-$-130.9M-$-94.78M-$-68.05M-$-44.09M-$-29.25M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$60.5M$95.3M$11.9M$34.8M$48.3M
Total investments$0.00$0.00$0.00$0.00$50K
Total debt$110K$220K$0.00$60K$0.00
Net debt-$-65.88M-$-94.21M-$-14.45M-$-35.44M-$-49.64M
Cash flow statement
20252024202320222021
Net income-$-36.12M-$-26.73M-$-23.96M-$-14.84M-$-10.46M
Depreciation and amortization$20K$10K$10K$10K$0.00
Stock-based compensation$1.33M$840K$1.08M$980K$510K
Change in working capital$6.28M-$-3.48M$1.78M-$-280K-$-2.22M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$1.1M-$-950K$1.45M-$-790K-$-870K
Net cash provided by operating activities-$-26.39M-$-14.56M-$-21.05M-$-13.55M-$-8.8M
Investments in property, plant and equipment-$-30K-$-10K$0.00-$-540K-$-250K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-2.03M-$-14.76M$0.00-$-540K-$-250K
Common stock issued-$-20K$109.3M$0.00-$-100K$53.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-20K$109.3M$0.00-$-100K$58.4M
Net change in cash-$-28.43M$80M-$-21.05M-$-14.14M$49.3M
Cash at end of period$66M$94.4M$14.5M$35.5M$49.7M
Operating cash flow-$-26.39M-$-14.56M-$-21.05M-$-13.55M-$-8.8M
Capital expenditure-$-30K-$-14.76M$0.00-$-540K-$-250K
Free cash flow-$-26.42M-$-29.31M-$-21.05M-$-14.09M-$-9.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Context Therapeutics Inc.

        Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

        CEO
        Martin A. Lehr
        Employees
        15
        Beta
        1.75

        Explore

        Frequently asked questions

        What is the intrinsic value of Context Therapeutics Inc. (CNTX)?

        InvestorsCraft does not currently publish an intrinsic value for CNTX. How the IC value is calculated.

        Is CNTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CNTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.